Grifols, ES0171996087

Grifols stock gains after Canadian Plasma Resources acquisition

Published on 09/18/2026 at 14:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Grifols stock closed at EUR 9.71 on September 17, 2026, after the company completed its acquisition of Canadian Plasma Resources. The latest half-year figures show revenue and EBITDA growth, while analysts remain cautious on leverage and cash flow.

Fotorealistische Plasma-Fraktionierungsanlage, Biotech-Produktion, unbeschriftete Industriehalle — Fotorealistische Ansicht einer Plasma-Fraktionierungsanlage zeigt Grifols S.A. ES0171996087 in moderner Biotech-Produktion mit Reinraumtechnik, Illustration mit AI erstellt.

Grifols, S.A. stock (ISIN ES0171996087) ended the last completed trading day at EUR 9.71 on BME Madrid as of September 17, 2026, reflecting a modest recovery from earlier in the year. As reported on September 18, 2026, the company has completed the acquisition of Canadian Plasma Resources, adding further scale to its plasma collection network and giving investors a fresh catalyst to reassess the stock.

Acquisition expands plasma collection footprint

According to El Nacional on September 18, 2026, Grifols has completed the purchase of Canadian Plasma Resources, a transaction that adds multiple collection centers in Canada to its global network. The deal strengthens Grifols' access to plasma, the key raw material for its immunoglobulin and other plasma-derived therapies, which is central to its long-term growth strategy.

For investors, the acquisition matters because Grifols' ability to secure sufficient plasma volumes underpins future revenue and margin development. By integrating Canadian Plasma Resources into its operations, Grifols aims to improve supply security and potentially lower unit collection costs over time compared with relying solely on existing centers, a factor that could support profitability in coming reporting periods.

Stock performance and recent price levels

Per a detailed overview on September 18, 2026, Grifols stock most recently closed at EUR 9.71 on BME Madrid on September 17, 2026, up 1.55% over the preceding five trading days and down 9.27% since January 1, 2026, highlighting the mixed performance year to date. The same price snapshot shows that the stock has traded around this level in recent sessions, with only small daily fluctuations and volumes in the several hundred thousand shares range.

In the broader context, the current price near EUR 9.71 stands slightly below the closing level of EUR 9.82 recorded on September 11, 2026, when daily trading volume reached roughly 714,000 shares, indicating that the stock has given back a small portion of its early September gains. Historically, the shares have been volatile, and the year-to-date decline of about 9.27% from the level at the start of 2026 underscores continued investor caution despite operational progress.

Latest reported figures and leverage concerns

Grifols' most recent half-year report for the six months to June 30, 2026, showed year-on-year growth in revenue and operating earnings compared with the prior-year period, as the company benefited from higher plasma volumes and improved product mix in its Biopharma segment. Revenue for the half-year increased by double-digit percentages versus the same period in 2025, while adjusted EBITDA rose more strongly, illustrating operating leverage as higher sales translated into faster profit growth.

However, leverage and cash generation remain key watchpoints for analysts. The latest figures indicate that net debt is still substantial relative to EBITDA, and while the half-year cash flow improved compared with the prior year, it has not yet fully allayed concerns over balance-sheet flexibility. As a result, several analyst commentaries in recent days have emphasized the importance of continued deleveraging and disciplined capital allocation, particularly following acquisitions such as Canadian Plasma Resources.

Analyst stance and valuation context

Recent analyst views captured in market overviews show a cautiously optimistic stance on Grifols stock, with average price targets moderately above the current BME price level but not signaling aggressive upside. One aggregated coverage snapshot published around mid-September 2026 points to an average target that sits roughly 10% to 20% above the EUR 9.71 reference price, implying that the market expects some recovery as operational improvements and integration benefits materialize.

At the same time, the valuation multiples derived from the current share price and the latest half-year EBITDA suggest that Grifols trades at a discount to some plasma-focused peers, reflecting lingering worries about leverage and historical accounting controversies. For investors, the combination of a subdued share price, improving operating trends and a strengthened plasma collection network after the Canadian Plasma Resources acquisition makes the upcoming quarterly updates and any guidance revisions critical checkpoints.

Grifols stock near recent range

Grifols stock most recently closed at about EUR 9.71 on BME Madrid for the session on September 17, 2026, with a modest positive change over five days but still down nearly 9.3% since the start of 2026. This leaves the shares trading slightly below their early September closing level of EUR 9.82, and investors will be watching whether the Canadian Plasma Resources acquisition and ongoing earnings momentum can lift the stock sustainably above this recent trading range.